Role and significance of In Vitro-Diagnostics in the health care systems of the future
International expert meeting / June 16th &17th, 2010
French Embassy in Germany, Wilhelmstr 69, 10117 Berlin
Wednesday, June 16th, 2010
Address of Welcome
14:00 Bernard de Montferrand, French Ambassador to Germany
14:10 Rudolf Tauber, Charité University Medicine,
Berlin
Session 1:
IVD in the health care system of Germany, UK and France / Present Status
14:20 - 16:00
Chair: Rudolf Tauber, Charité University Medicine,
Berlin
14:20
In Vitro-Diagnostics in the health care system of
Germany
Karl Lackner, University of Mainz/German Society for
Clinical Chemistry and Laboratory Medicine (DGKL),
Mayence
14:45 Designing biomarkers: the challenges for the
personalized medicine of the future
Christine M'Rini, Institut Mérieux, Lyon
15:10
A partnership to deliver stratified medicine in cancer in
the UK
James Peach, Cancer Research UK (CRUK), London
15:35
Understanding the regulation of In Vitro-Diagnostics in
urope
Doris-Ann Williams, British In-Vitro Diagnostics
Association (BIVDA), London
Session 2:
Point of Care Testing (POCT)
16:30 - 18:00
Chair: Penny Wilson, Technology Strategy Board, Swindon
16:35
Future Directions in PoC Testing - An Industry View
Nicholas Smith, Roche Diagnostics AG, Rotkreuz
17:00
How can nano and microtechnology increase POCT development?
Two examples on how silicon and single use lab on a chip
can be compatible
Christine Peponnet, CEA-Leti, Grenoble
17:25 Clinically useful Point of Care Diagnostics for
Infectious Agents
Penny Wilson, Technology Strategy Board, Swindon
Thursday, June 17th, 2010
Session 3:
The search for new biomarkers
08:30 - 10:00
Chair: Jean Chabbal, CEA-Leti, Grenoble
08:35 Clinical validation strategies for new biomarkers
François Berger, Inserm, Grenoble
09:00
Metabolite profiling - a promising tool for identification
and validation of novel biomarkers
Tim Bölke, metanomics health GmbH, Berlin
09:25
Screening for novel oncology biomarker panels using both
DNA and protein microarrays
John Anson, Oxford Gene Technology, Oxford
Session 4:
IVD and prevention
10:30 - 12:00
Chair: Rudolf Tauber, Charité University Medicine,
Berlin
10:35 Theranostic biochips - From biosensors to
personalised medicine
Till Bachmann, Division of Pathway Medicine, University of
Edinburgh, Edinburgh
11:00 EuromeDiag: a new European cluster in the medical
Diagnostic field
Daniel Laune, SysDiag-CNRS/BioRad, Montpellier
11:25
Prevention of cardiovascular diseases
Michael Walter, Unfallkrankenhaus Berlin, Berlin
Session 5:
IVD and therapy I
13:30 - 15:00
Chair: Steve Little, QIAGEN, Manchester
13:35
Influence of predictive molecular pathology on therapeutic
decisions in oncology and infections
Carsten Denkert, Charité University Medicine, Berlin
14:00 High throughput RNAi and theragnostic
Xavier Gidrol, CEA, Grenoble
14:25
Business Models for Personalized Healthcare
Steve Little, QIAGEN, Manchester
Session 6:
IVD and therapy II
15:30 - 17:00
Chair: Jean Chabbal, CEA-Leti, Grenoble
15:35 Biomarkers in preclinical and clinical drug
development
Ulrike Fiedler, ProQinase GmbH, Fribourg
16:00
Rare circulating cells as a non-invasive approach to the
monitoring of targeted therapy in patients with cancer;
potential application to prenatal diagnosis
Yvon Cayre, Hôpital René Debré, Paris
16:25
In Vitro-Diagnostics and the value proposition of
stratified medicines
Eddie Blair, Integrated Medicines Ltd, Cambridge
17:00
Closing remarks & questions
Frank Bier, Fraunhofer IBMT, Berlin